Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22353089 | 0.77 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL10926831 | 0.75 | SLC22A12 (1.00) | XDHSLC22A12 | |
| SCHEMBL16700088 | 0.75 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL17941561 | 0.74 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL17941585 | 0.74 | XDH (0.65) | XDHSLC22A12 | |
| SCHEMBL17010244 | 0.74 | XDH (0.77) | XDHSLC22A12 | |
| SCHEMBL17941590 | 0.74 | XDH (0.64) | XDHSLC22A12 | |
| SCHEMBL19092939 | 0.73 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL16708623 | 0.73 | XDH (0.78) | XDHSLC22A12 | |
| SCHEMBL17010240 | 0.73 | XDH (0.78) | XDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161835-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200339545-A1 | Compounds And Their Use For Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10752613-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339545-A1 | Compounds And Their Use For Reducing Uric Acid Levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885 |
| US-11161835-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885 |
| US-10752613-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885SLC22A12 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.